Transglutaminase 2 Expression and Its Prognostic Significance in Clear Cell Renal Cell Carcinoma
Min Jee Park, Hae Woon Baek, Ye-Young Rhee, Cheol Lee, Jeong Whan Park, Hwal Woong Kim, Kyung Chul Moon
J Pathol Transl Med. 2015;49(1):37-43.   Published online 2015 Jan 15     DOI:
Citations to this article as recorded by Crossref logo
Application of a Fluorescence Anisotropy-Based Assay to Quantify Transglutaminase 2 Activity in Cell Lysates
Sandra Hauser, Paul Sommerfeld, Johanna Wodtke, Christoph Hauser, Paul Schlitterlau, Jens Pietzsch, Reik Löser, Markus Pietsch, Robert Wodtke
International Journal of Molecular Sciences.2022; 23(9): 4475.     CrossRef
The Biological and Biomechanical Role of Transglutaminase-2 in the Tumour Microenvironment
Robert Tempest, Sonia Guarnerio, Rawan Maani, Jamie Cooper, Nicholas Peake
Cancers.2021; 13(11): 2788.     CrossRef
A Precision Strategy to Cure Renal Cell Carcinoma by Targeting Transglutaminase 2
Soo-Youl Kim, Jeffrey W. Keillor
International Journal of Molecular Sciences.2020; 21(7): 2493.     CrossRef
Evaluation of nuclear NF-κB, transglutaminase2, and ERCC1 as predictors of platinum resistance in testicular tumors
Alan A. Azambuja, Paula Engroff, Bruna T. Silva, Roberta C. S. Zorzetti, Fernanda B. Morrone
International braz j urol.2020; 46(3): 353.     CrossRef
Transglutaminase 2-Mediated p53 Depletion Promotes Angiogenesis by Increasing HIF-1α-p300 Binding in Renal Cell Carcinoma
Seon-Hyeong Lee, Joon Hee Kang, Ji Sun Ha, Jae-Seon Lee, Su-Jin Oh, Hyun-Jung Choi, Jaewhan Song, Soo-Youl Kim
International Journal of Molecular Sciences.2020; 21(14): 5042.     CrossRef
Role of Tissue Transglutaminase Catalytic and Guanosine Triphosphate-Binding Domains in Renal Cell Carcinoma Progression
Burge Ulukan, Ajna Bihorac, Tarik Sipahioglu, Robert Kiraly, Laszlo Fesus, Dilek Telci
ACS Omega.2020; 5(43): 28273.     CrossRef
Transglutaminase 2: The Maestro of the Oncogenic Mediators in Renal Cell Carcinoma
Ayca Ece Nezir, Burge Ulukan, Dilek Telci
Medical Sciences.2019; 7(2): 24.     CrossRef
Transglutaminase 2 takes center stage as a cancer cell survival factor and therapy target
Richard L. Eckert
Molecular Carcinogenesis.2019; 58(6): 837.     CrossRef
Allosteric inhibition site of transglutaminase 2 is unveiled in the N terminus
Nayeon Kim, Joon Hee Kang, Won-Kyu Lee, Seul-Gi Kim, Jae-Seon Lee, Seon-Hyeong Lee, Jong Bae Park, Kyung-Hee Kim, Young-Dae Gong, Kwang Yeon Hwang, Soo-Youl Kim
Amino Acids.2018; 50(11): 1583.     CrossRef
Renal Cell Carcinoma Is Abrogated by p53 Stabilization through Transglutaminase 2 Inhibition
Seon-Hyeong Lee, Won-Kyu Lee, Nayeon Kim, Joon Kang, Kyung-Hee Kim, Seul-Gi Kim, Jae-Seon Lee, Soohyun Lee, Jongkook Lee, Jungnam Joo, Woo Kwon, Sun Rha, Soo-Youl Kim
Cancers.2018; 10(11): 455.     CrossRef
Tissue transglutaminase expression is necessary for adhesion, metastatic potential and cancer stemness of renal cell carcinoma
Yesim Bagatur, Ayca Zeynep Ilter Akulke, Ajna Bihorac, Merve Erdem, Dilek Telci
Cell Adhesion & Migration.2017; : 1.     CrossRef
Characterization of clear cell renal cell carcinoma by gene expression profiling
Bryan J. Thibodeau, Matthew Fulton, Laura E. Fortier, Timothy J. Geddes, Barbara L. Pruetz, Samreen Ahmed, Amy Banes-Berceli, Ping L. Zhang, George D. Wilson, Jason Hafron
Urologic Oncology: Seminars and Original Investigations.2016; 34(4): 168.e1.     CrossRef
Prognostic role of tissue transglutaminase 2 in colon carcinoma
María Jesús Fernández-Aceñero, Sofía Torres, Irene Garcia-Palmero, Cristina Díaz del Arco, J. Ignacio Casal
Virchows Archiv.2016; 469(6): 611.     CrossRef